|Illustration of the |
The initial news appeared on May 9, 2005 on pages 29 and 30 with the following headlines:
Genetic brake to lung cancer - New drugs improve the prognosis of patients who have a mutated EGFR gene.
The text echoed the discovery of drugs that act by inhibiting the action of a gene (EGFR), whose deleterious mutation can lead to the appearance of cancer (disordered multiplication of cells).
July 3, 2005, pages 30 and 31: A brake to lung cancer. Informs on a debate
about the discovery, commented two months before.
|Illustration of news nr. 6|
2. July 4, 2005, page 34: Advances in early detection of lung cancer predict survival improvements. A comment on a congress held in Barcelona, where the subject was discussed.
3. May 14, 2008, page 72: Interview to Josep Baselga, who had researched about this subject.
4. July 3, 2008, page 29: A blood test indicates whether a cancer patient responds to therapy.
5. November 1, 2008, page 26: Spanish doctors improve the treatment of lung cancer. More about the blood test to detect the mutation of the EGFR gene.
6. August 20, 2009, page 21: A genetic test improves the treatment of lung cancer. Describes the use of drugs against the mutated EGFR gene.
7. December 1, 2009, page 24: Cancer: detection in blood. More on the detection of the EGFR mutation through a test.
8. January 4, 2011, pages 20 and 21: A genetic ID for each tumor. This is the first time it is noted that not all people treated with anti-mutated EGFR drugs respond to treatment. If the KRAS gene is also mutated (a mutation affecting 40% patients), these drugs will not work.
9. March 27, 2011, pages 34 and 35: Doctors in Can Ruti improve the treatment of lung cancer. More research on why some patients do not respond to drugs. The presence of a certain protein (NF-KB) prevents the drugs from taking effect.
10. July 2, 2012, page 25: Doctors discover why some cancers stop responding to therapy. Another protein (AXL) also prevents the action of the anti-mutated EGFR drugs.
11. October 21, 2013, page 24: A patent against cancer. Discovery of a new mutation in the EGFR gene that prevents the action of drugs against colorectal cancer.
12. January 26, 2014, page 18: Genetic data to heal better. The company Pangea Biotech validates a machine that analyzes the mutations of the EGFR gene.
The same post in Spanish